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Human lymphoblastoid TK6 and WTK-1 cells are widely used to detect mutagens in vitro.  TK6 cells 
have wild-type TP53 alleles,  while WTK-1 cells have one allele of mutated TP53.  Both cells were 
treated with 5-ﬂuorouracil (5-FU),  and gene mutation assay and micronucleus assay were performed 
to clarify the diﬀerential response related to the TP53 gene status.  The eﬀects of 5-FU on gene 
expression were assessed by microarray and quantitative RT-PCR analyses.  In WTK-1 cells,  5-FU 
increased the frequency of cells with micronucleus and mutation.  In TK6 cells,  frequency of cells with 
micronucleus was increased but the mutation frequency was not.  The cytotoxicity induced by 5-FU 
was more prominent in TK6 cells than in WTK-1 cells.  Analysis of gene expression showed that the 
genes involved in the TP53 pathway were up-regulated in TK6 cells but not in WTK-1 cells.  The dif-
ferential responses to 5-FU between these cell lines appeared to be due to the diﬀerence in the TP53 
gene status,  thus providing a molecular basis for the bioassays using these cell lines in the toxicology 
ﬁeld.  Our results indicate that the clinical eﬃcacy of 5-FU chemotherapy may depend on the TP53 
genotype.
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n the toxicology ﬁeld,  there are many ways to 
assess the adverse eﬀects of poisons on humans.  
Gene mutation assays (Tk mutation assays) and in vitro 
micronucleus assays detect DNA damage and chromo-
somal aberration,  respectively.  These studies are 
performed as screening tests for carcinogenicity.  
Human lymphoblastoid TK6 cells and WTK-1 cells are 
widely used in Tk mutation assays or in vitro micronu-
cleus assays.  These cells are heterozygous at the Tk 
locus,  where loss of heterozygosity (LOH) by DNA 
damage leads to the detection of mutants by resistance 
to the selective agent (triﬂuorothymidine) [1-4].
　 TK6 and WTK-1 cells are both derived from 
WIL-2 cells that were originally derived from a 
5-year-old male with hereditary spherocytosis and were 
transformed by the Epstein-Barr virus [5].  TK6 and 
WTK-1 cells are not classiﬁed as lymphoma or leuke-
mia,  and there is no data indicating that these cell 
lines have tumorigenic activity in vivo.  TK6 cells have 
wild-type TP53 tumor suppressor genes,  while WTK-1 
cells have a mutant TP53 gene [6].  The TP53 gene in 
WTK-1 cells is mutated at codon 237 of exon 7,  which 
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is the part of the central DNA binding domain [6].  
TK6 and WTK-1 cells are useful for examining the 
function of TP53 status,  because these cells have an 
almost identical genetic background except for TP53 
status.
　 TP53 protein is involved in DNA repair,  G1 
checkpoint activation,  and induction of apoptosis [7].  
Wild-type TP53 leads cells with reparable DNA dam-
age into cell cycle arrest,  allowing repair of the dam-
age,  and cells with severe DNA damage to apoptosis,  
although mutated TP53 does not.  The expression of 
genes related to apoptosis,  the cell cycle,  and DNA 
repair was up-regulated in TK6 cells than in WTK-1 
cells after treatment of direct DNA damaging agents 
and irradiation of X-ray [8,  9].
　 Earlier studies have shown that,  compared with 
TP53 mutant or null cells,  TP53 wild-type cells 
undergo apoptosis earlier or at a higher frequency 
following severe cytotoxicity induced by X-rays or 
certain chemicals [3,  6,  10-13].  TP53 mutant cells 
diﬀer from the wild-type cells in their cytotoxic and 
mutagenic responses to some mutagens [14-17].  Some 
clastogens and spindle poisons are more cytotoxic in 
wild-type cells than in mutant cells and,  at equal levels 
of cytotoxicity,  are more clastogenic in the mutant 
cells [3,  18].  The spontaneous mutation frequency in 
WTK-1 cells is 100－200×10－6,  while it is less than 
10×10－6 in TK6 cells [14].  WTK-1 cells are more 
resistant than are TK6 cells to X-rays and other 
mutagens [14].  These diﬀerences may be due to dif-
ferences in TP53 status.
　 5-Fluorouracil (5-FU),  a pyrimidine base analog,  
competitively inhibits DNA synthesis via the inhibi-
tion of thymidylate synthetase (TS) [19-21].  5-FU is 
clastogenic in mammalian cells [22] in vitro and in vivo 
[23] but is not mutagenic to Salmonella typhimurium 
[22].  5-FU induces neither chromosomal aberrations 
nor sister chromatid exchanges in the human materials 
studied so far [24].  However,  it was not clear that 
the diﬀerence in status of p53 in human materials is 
related to the degree of DNA damage induced by 
5-FU.  In addition,  the carcinogenic activity of 5-FU 
has not yet been fully assessed in clinical trials.
　 In our previous report [25],  3h treatment with 
5-FU increased mutation frequency in mouse lym-
phoma cells but not in TK6 or WTK-1 cells.  
However,  5-FU was known to inhibit the DNA syn-
thesis more successfully in longer-term treatment than 
in short-term treatment [26],  and 5-FU and its related 
drugs are used frequently in long-term administration 
in clinical trials.
　 We aimed to determine the potential of 5-FU for 
mutagenicity after long-term (24h) treatment in human 
cell lines.  Furthermore,  the gene expression proﬁle 
after 5-FU treatment was analyzed to examine 
whether there was a diﬀerential response between 
these cell lines compared with the direct DNA damag-
ing agents such as alkylating agents or X-ray.
Materials and Methods
　 Chemical and cell lines. 5-FU (CAS No.  
51-21-8) was purchased from Wako Pure Chemicals 
Industries,  Ltd.  (Osaka,  Japan) and dissolved in 
physiologic saline just before use.
　 TK6 and WTK-1 cells were provided by Hatano 
Research Institute at the Food and Drug Safety 
Center.  The cells were cultured in RPMI 1640 
medium (Gibco,  Invitrogen Corp.,  Carlsbad,  CA,  
USA) containing 10v/vｵ horse serum (Gibco,  
Invitrogen Corp. ) at 37℃ in an atmosphere of 5ｵ 
CO2 and high humidity.
　 Mutation analysis of the TP53 gene. Genomic 
DNA was isolated from the cell lines by SDS/protei-
nase K treatment,  phenol-chloroform extraction,  and 
ethanol precipitation.  Coding exons of the TP53 gene 
were ampliﬁed with the intronic primers as follows:  
sense 5 -ʼGAC TGC TCT TTT CAC CCA TCT A and 
antisense 5ʼ-TGC AGG GGG ATA CGG CCA G for 
exon 4,  sense 5ʼ-TTT GCT GCC GTG TTC CAG 
TTG and antisense 5ʼ-ACC CTT AAC CCC TCC 
TCC CA for exon 5-6,  sense 5ʼ-CTT GGG CCT 
GTG TTA TCT CCT and antisense 5ʼ-CGC CGG 
AAA TGT GAT GTG AGG for exon 7,  sense 
5ʼ-CCT TAC TGC CTC TTG CTT CTC and anti-
sense 5ʼ-GAT AAG AGG TCC CAA GAC TTA G for 
exon 8-9.  PCR products were puriﬁed with exonu-
clease I and shrimp alkaline phosphatase (USB 
Corporation,  Cleveland,  OH,  USA),  reacted with a 
Big Dye Terminator (Applied Biosystems,  Foster 
City,  CA,  USA),  and analyzed on an ABI 3130 
sequencer (Applied Biosystems).
　 Tk mutation assay. Considering its cytotoxic-
ity,  the dose levels of 5-FU were selected as 0.125,  
0. 25,  0.5,  and 1.0µg/mL for 24h in TK6 and WTK-1 
cells in Tk mutation assays.  The Tk mutation assays 
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were performed by the microwell method [14].  
Namely,  the cells (2×106 cells,  cell density at 2×
105/mL) were treated at 37℃ for 24h and washed.  A 
portion of the cells was seeded onto 96-well plates,  
and the plating eﬃciency (PE) was measured on day 0 
after 5-FU treatment (PE0).  The remaining cells 
were cultured for 72h to allow phenotypic expression.  
The cells were seeded onto 96-well plates in the pres-
ence of triﬂuorothymidine (TFT,  CAS No.  70-00-8,  
Sigma Chemical Co.,  St.  Louis,  MO,  USA) for assess-
ment of mutation frequency.  Another portion of the 
cells was seeded onto 96-well plates in the absence of 
TFT for the measurement of plating eﬃciency after 
the expression period.
　 The plates were incubated for 12-14 days,  and the 
number of wells containing colonies was then counted,  
allowing us to evaluate the mutation frequency [14].  
Mutation frequency and relative cell survival from 
PE0 were calculated as previously described [27].
　 In vitro micronucleus assay. The cells were 
treated by 5-FU in the same manner as in the Tk 
mutation assay.  The micronucleus (MN) assay speci-
mens were prepared 48h after 5-FU treatment,  as 
previously described [28].  Brieﬂy,  106 to 3×106 
cells were treated with hypotonic (75mM) KCl solu-
tion,  ﬁxed in methanol-acetic acid (1 : 3),  resuspended 
in methanol containing 1ｵ (v/v) acetic acid,  and 
placed onto glass slides in sample drops.  The speci-
mens were stained with acridine orange (Wako Pure 
Chemicals Industries,  Ltd. ) and were observed with 
the aid of a ﬂuorescence microscope with a 470-490 
nm excitation ﬁlter.  One thousand cells from each 
treatment group were observed,  and we counted the 
number of cells with MN.  Cells were considered to be 
positive for MN when the diameter of MN was less 
than half the diameter of the main nucleus.  We 
excluded cells with an abnormal main nucleus from this 
analysis.
　 Analysis of gene expression by microarray.
The gene expression after 1µg/mL of 5-FU treatment 
for 24h was analyzed by Agilent Microarray.  Total 
RNA was extracted from 0.2－6×106 cells after 
5-FU treatment.  Total RNA was prepared using 
RNeasy Mini kit (Qiagen,  Inc.,  Hilden,  Germany) 
according to the manufacturerʼs instructions.  RNA 
samples were ampliﬁed and Cy3-labeled using the 
Agilent Low Input Quick Amp Labeling Kit (Agilent 
Technologies,  Santa Clara,  CA,  USA) following the 
manufacturerʼs instructions.  The hybridization was 
performed according to the Agilent 60-mer oligo 
microarray processing protocol using the Agilent Gene 
Expression Hybridization Kit (Agilent Technologies).  
Brieﬂy,  1.65µg Cy3-labeled fragmented cRNA was 
hybridized overnight (17h,  65℃) to Agilent Whole 
Human Genome Oligo Microarrays 4×44K.  Fluores-
cence signals of the hybridized microarrays were 
detected using Agilentʼs Microarray Scanner System 
(Agilent Technologies).  The Agilent Feature Extrac-
tion Software was used to read out and process the 
microarray image ﬁles.
　 The signal intensities were normalized by dividing 
the intensity values by their median.  The genes with 
considerable change of expression,  more than 2-fold 
and with a p-value less than 0.01 compared with the 
solvent control,  were selected by the Resolver® 
Software (Agilent Technologies).  The analysis of 
function of the genes with changed expression after 
5-FU treatment was done by DAVID bioinformatics 
resources ver. 6.7.
　 Analysis of gene expression by quantitative 
RT-PCR. The gene expression after 1µg/mL of 
5-FU treatment for 24h was analyzed by TaqMan® 
Gene Expression Assays.  Total RNA was extracted 
in the same manner as the analysis by microarray.  
Total RNA was reverse-transcribed by High Capacity 
cDNA Reverse Transcription Kits (Applied Biosys-
tems) according to the manufacturerʼs instructions.  
TaqMan® Gene Expression Master Mix (Applied Bio-
systems) was used for quantitative RT-PCR,  and 
20ng of cDNA was used as the template.  TaqMan® 
Gene Expression Assays (Applied Biosystems) with 
assay IDs Hs00180269_m1,  Hs00355782_m1,  
Hs00540450_s1,  and Hs00266705_g1 were used for 
analysis of Bax,  p21,  MDM2,  and GAPDH,  respec-
tively.
　 PCR conditions consisted of one cycle at 50℃ for 
2min followed by 95℃ for 10min and 40 cycles of 2 
segments (95℃ for 15s,  60℃ for 1min) using ABI 
7500 realtime PCR system (Applied Biosystems).  
Each sample was normalized using GAPDH as a refer-
ence for overall expression level.
　 Statistical analysis. When the mutation fre-
quency increased signiﬁcantly compared with the 
vehicle control by Dunnettʼs test,  5-FU treatment was 
judged to be positive in Tk mutation assay.  In the 
analysis of cytotoxicity (PE0),  the number of wells 
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containing colonies was compared with the vehicle 
control by chi-square test.  The conditional binomial 
test was performed to judge the positive response in 
MN frequency.  The gene expression by Quantitative 
RT-PC was analyzed by Studentʼs t-test.  SAS (sys-
tem release 8.2) or Microsoft Excel was used for sta-
tistical analysis.  P values ＜0.05 were taken as sig-
niﬁcant.
Results
　 Tk mutation assay and in vitro micronucleus 
assay. Initially,  the TP53 gene of WTK-1 and 
TK6 cells was analyzed by DNA sequencing,  and it 
was conﬁrmed that methionine (ATG) was substituted 
by isoleucine (ATA) at codon 237 in exon 7 of the 
TP53 gene in WTK-1 cells (Fig.  1A).
　 5-FU was cytotoxic in both cell lines in a concen-
tration-dependent manner (Fig.  1B).  The cell survival 
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Fig. 1　 TP53 mutation,  cytotoxicity,  and mutation frequency of TK6 and WTK-1 cells.  Sequencing results of exon 7 in the TP53 gene 
(A),  cell survival (B),  and mutation frequency after 24h treatment with 5-FU (C),  in TK6 (left) and WTK-1 cells (right).  MF,  mutation 
frequency.  The TP53 gene in TK6 cells has no mutation; however,  the TP53 gene in WTK-1 cells has the substitution of isoleucine (ATA) 
for methionine (ATG) at codon 237 in exon 7 (A).  The concentration-dependent cytotoxicity was shown in TK6 and WTK-1 cells after 5-FU 
treatment and was more severe in TK6 cells than in WTK-1 cells (B).  5-FU increased MF about 2-fold relative to the solvent control at 
1.0µg/mL or more In WTK-1 cells but not in TK6 cells (C).
＊signiﬁcant diﬀerence (p＜0.05) from the vehicle control by chi-square test (B) and Dunnettʼs test (C).  Note that the scale of MF in 
WTK-1 cells is 25-fold higher than that inTK6 cells.
rate was decreased signiﬁcantly in 1.0 and 2.0µg/mL 
in WTK-1 cells,  while that in TK6 cells was 
decreased signiﬁcantly in 0.125µg/mL or more (p＜
0.05).  Thus,  the cytotoxicity induced by 5-FU was 
more severe in TK6 cells than in WTK-1 cells.  In 
WTK-1 cells,  5-FU increased the mutation frequency 
signiﬁcantly compared with the solvent control at 
concentrations of 1.0µg/mL or more and was judged 
as positive in Tk mutation assay (p＜0.05) (Fig.  1C).  
However,  5-FU was not mutagenic to TK6 cells.
　 5-FU increased the frequency of cells with micro-
nucleus (MN frequency) in WTK-1 cells in a concen-
tration-dependent manner,  increasing the MN fre-
quency to 2.7 and 4.0 times the control value at 0.5 
and 1.0µg/mL,  respectively (p＜0.05) (Fig.  2).  In 
TK6 cells,  5-FU increased the MN frequency (to 2.0 
times the control value) at 1.0µg/mL only.
　 Microarray analysis. The changes of gene 
expression were analyzed in a 5-FU treatment group 
compared with the solvent control.  The numbers of 
up-regulated (more than 2-fold and p-value ＜0.01) 
genes were 520 and 245 in TK6 and WTK-1 cells,  
respectively,  and the numbers of down-regulated (less 
than 0.5-fold and p-value ＜0.01) genes were 271 and 
212 in TK6 and WTK-1 cells,  respectively (Fig.  3).  
The possible function of the up-regulated genes in 
TK6 cells treated with 5-FU is shown in Table 1.  In 
TK6 cells,  the genes related to the TP53 signaling 
pathway,  involved in processes such as apoptosis and 
DNA damage response,  were up-regulated,  but this 
was not the case in WTK-1 cells.  Namely,  the BAX,  
BBC3,  FAS,  SESN1,  SESN2,  p21 (CDK1A),  DDB2,  
and GADD45A genes were up-regulated after 5-FU 
treatment in TK6 cells (Table 2 and Fig.  4).  The 
genes involved in the negative feedback to the TP53 
pathway (MDM2 and Cyclin G) were also up-regulated 
after 5-FU treatment in TK6 cells.  In WTK-1 cells,  
however,  the genes related to the TP53 pathway or 
negative feedback to the TP53 pathway were not 
changed.  None of the genes related to cytotoxicity,  
cell death,  or gene mutation were found in down-reg-
ulated genes in TK6 cells or WTK-1 cells (data not 
shown).
　 Quantitative RT-PCR. The BAX,  p21,  and 
MDM2 genes were selected as target genes for analy-
sis of quantitative RT-PCR because all are key genes 
for apoptosis,  cell cycle regulation,  and negative 
feedback to the TP53 gene,  and all showed marked 
elevation in gene expression after 5-FU treatment in 
the microarray analysis.  The expressions of the BAX,  
p21,  and MDM2 genes after 5-FU treatment are shown 
in Fig.  5.  The expression increased signiﬁcantly in 
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Fig. 2　 In vitro micronucleus assay in TK6 and WTK-1 cells after 5-FU treatment for 24h.  MN＋ cells,  The frequency of the cells having 
micronucleus 5-FU increased the MN frequency in WTK-1 cells,  to 2.7,  and 4 times the control value at 0.5 and 1.0µg/mL of 5-FU,  
respectively.  In TK6 cells,  5-FU increased MN frequency (2.0 times of the control value) at 1.0µg/mL only.
＊signiﬁcant diﬀerence (p＜0.05) from the vehicle control by the conditional binomial test.
TK6 cells (p＜0.05) but not in WTK-1 cells.  Thus,  
these results conﬁrmed the representative results of 
the microarray analyses.
Discussion
　 In this study,  the relationship between cytotoxicity 
or mutagenicity and genetic status of the TP53 gene 
was analyzed in 2 cell lines with or without TP53 
mutation after 5-FU treatment.  Both TK6 and WTK-1 
cells are derived from WIL-2 cells [5],  but only 
WTK-1 cells have the homozygous mutant TP53 gene 
[6].  A ﬂuorinated pyrimidine base analogue,  5-FU,  
is converted to 5-ﬂuoro-2-deoxyuridylate monophos-
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TK6 cells WTK-1 cells 
TK6 Gene 
Up 520
Down 271
WTK-1 Gene
Up 245
Down 212
P<0.01 P<0.01
A
B
Fig. 3　 The changes of gene expression in the cells treated with 5-FU for 24h.  The changes of gene expression between 5-FU treat-
ment group with the solvent control group (A),  the numbers of genes changed expression more than 2-fold and p-value 0.01 compared with 
control (B).  The numbers of up-regulated (more than 2-fold and p-value ＜0.01) genes were 520 and 245 in TK6 and WTK-1 cells,  respec-
tively,  and the numbers of down-regulated (less than 0.5-fold and p-value ＜0.01) genes were 271 and 212 in TK6 and WTK-1 cells,  
respectively.
Table 1　 Changes in mRNA expression related to TP53 activity in TK6 cells after 5-FU treatment (Up-regulation)
Function Gene counts p-value
TP53 signaling pathway 15 ＜0.00001
Regulation of cell proliferation 34 ＜0.00001
Induction of apoptosis by intracellular signals 8 0.00004
DNA damage response,  signal transduction by TP53 class mediator 6 0.00007
Regulation of apoptosis 30 0.00013
Response to DNA damage stimulus 17 0.00074
In TK6 cells,  the genes implicated in the TP53 signaling pathway,  apoptosis,  and DNA damage response were changed in 5-FU-treated 
group compared with the solvent control group but not in WTK-1 cells.  The analysis was performed by the DAVID bioinformatics resources 
ver. 6.7.
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Table 2　 Up-regulated mRNA involved in the TP53 pathway,  apoptosis and cell cycle in TK6 cells
Gene Name Gene Symbol
TK6 cells WTK-1 cells
Fold Change Fold Change
BCL2 binding component 3 BBC3 3.83 －1.06
BCL2-associated X protein BAX 2.36 －1.16
Cyclin G1 CCNG1 2.40 －1.06
Cyclin-dependent kinase inhibitor 1A (p21,  Cip1) CDKN1A 5.73 1.48
Cyclin-dependent kinase inhibitor 2B (p15,  inhibits CDK4) CDKN2B 11.78 1.08
Damage-speciﬁc DNA binding protein 2,  48kDa DDB2 2.76 －1.06
Fas (TNF receptor superfamily,  member 6) FAS 2.28 1.06
Forkhead box O1 FOXO1 2.18 1.04
Growth arrest and DNA-damage-inducible,  alpha GADD45A 2.79 1.09
Leucine-rich repeats and death domain containing LRDD 2.78 －1.01
MAX dimerization protein 4 MXD4 2.29 －1.16
Mdm2 TP53 binding protein homolog (mouse) MDM2 3.82 1.15
Homo sapiens hypothetical protein MGC5370,  mRNA 
(cDNA clone IMAGE: 3049213),  partial cds.  [BC006795] MGC5370 4.81 1.26
Nuclear protein,  transcriptional regulator,  1 NUPR1 12.84 1.97
Pleckstrin homology-like domain,  family A,  member 3 PHLDA3 3.79 1.48
Polymerase (DNA directed),  eta POLH 2.46 －1.35
Protein phosphatase 1D magnesium-dependent,  delta isoform PPM1D 2.02 1.10
Sestrin 1 SESN1 6.14 －1.04
Sestrin 2 SESN2 4.41 －1.05
TP53 regulated inhibitor of apoptosis 1 TRIAP1 2.41 －1.02
Tumor necrosis factor (ligand) superfamily,  member 4 TNFSF4 11.38 1.66
Tumor necrosis factor receptor superfamily,  member 4
mRNA for OX40 homologue.  [X75962]
TNFSF4 
X75962 5.34 1.30
Tumor protein TP53 inducible nuclear protein 1 TP53INP1 8.22 －2.14
Tumor protein TP53 inducible protein 3 TP53I3 16.39 1.62
Xeroderma pigmentosum,  complementation group C XPC 2.48 －1.15
Zinc ﬁnger,  matrin type 3 ZMAT3 4.54 1.13
The up-regulated (more than 2-fold and p-value ＜0.01) genes involved in the TP53 pathway after 5-FU treatment compared with the sol-
vent control were shown.  The genes up-regulated in TK6 cells were hardly up-regulated in WTK-1 cells.  (Analysis by the DAVID bioinfor-
matics resources ver. 6.7.)
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Fig. 4　 Change of gene expression in the TP53 pathway in TK6 cells after 5-FU treatment for 24h.
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Fig. 5　 The expression of mRNA after 24h 5-FU treatment on TK6 and WTK-1 cells.  The expressions of mRNA are shown in TK6 cells 
(upper column) and WTK-1 cells (lower column).  The expressions of BAX,  p21,  and MDM2 genes were up-regulated with greater fre-
quency in TK6 cells than in WTK-1 cells.
＊signiﬁcant diﬀerence (p＜0.05) from the vehicle control by Studentʼs t-test.
phate (FdUMP).  FdUMP complexes with TS and 
5, 10-methylene tetrahydrofolate (CH2FH4) and com-
petitively inhibits DNA synthesis [19-21,  29].  
Thymidine depletion by TS inhibition induces a nucle-
otide pool imbalance and the misincorporation of 
dUTP and/or misrepair of the uracil-containing lesion,  
causing double-strand DNA breaks (DSBs) [30-32].  
The direct incorporation of 5-ﬂuoro-deoxyuridine 
triphosphate (FdUTP) inhibits DNA synthesis [20].  
Therefore,  the intracellular metabolism of 5-FU to 
FdUMP or FdUTP leads to cytotoxic and mutagenic 
eﬀects.  5-FU is phosphorylated by orotate phosphor-
ibosyl transferase (OPRT) to ﬂuoro-uridylate mono-
phosphate and detoxiﬁed by dihydrouracil dehydroge-
nase (DPD) to ﬂuoro-β-alanine.  TS,  OPRT,  and/or 
DPD are the predictive factors for the response to 
5-FU and its derivative drugs [33,  34].  Compared 
with WTK-1 cells,  TK6 cells had much lower DPD 
activity,  and 5-FU in TK6 cells was eﬃciently 
metabolized to FdUMP without being detoxiﬁed.  The 
TS content was higher in TK6 cells than in WTK-1 
cells,  so 5-FU metabolism would not be very diﬀerent 
in TK6 and WTK-1 cells [25].
　 In general,  X-rays and mutagens induce more 
cytotoxicity and/or a higher frequency of apoptosis in 
cells with wild-type TP53 than in TP53 mutant cells,  
and a higher frequency of mutations and chromosomal 
aberrations in TP53 mutant cells than in wild-type 
cells [14].  In this study,  the cytotoxicity induced by 
5-FU was also more prominent in TK6 cells (TP53 
wild type) cells than in WTK-1 cells (TP53 mutant).  
Mutation frequency and chromosomal damage (MN 
frequency) occurred more in WTK-1 cells than in TK6 
cells after 5-FU treatment.  These results were simi-
lar to the response to X-ray or mutagens [8,  9].
　 In microarray analysis of gene expression,  a larger 
number of genes were up-regulated in TK6 cells than 
in WTK-1 cells; however,  the numbers of down-regu-
lated genes were almost equal.  BAX,  BBC3,  FAS,  
SESN1,  SESN2,  p21,  DDB2,  and GADD45A were 
up-regulated after 5-FU treatment in TK6 cells but not 
in WTK-1 cells.  These genes were implicated in the 
TP53 pathway (apoptosis,  cell cycle,  or DNA repair).  
MDM2 and Cyclin G,  involved in the negative feedback 
to the TP53 pathway,  were also up-regulated after 
5-FU treatment in TK6 cells.  In quantitative RT-PCR 
analyses,  the up-regulation of BAX,  p21,  and MDM2 
were ensured in TK6 cells but not in WTK-1 cells 
after 5-FU treatment.  Zschenker et al.  reported that 
an especially strong induction was seen for the p21,  
MDM2,  SESN1,  XPC,  DDB2,  and FUCA1 genes in 
TK6 cells after X-ray irradiation [9].  The direct 
DNA damaging agents also increased the expression of 
genes associated with the TP53 pathway related to 
regulation of the cell cycle or apoptosis in TK6 cells 
[8].  These results are consistent with our results.
　 In our previous study,  5-FU induced the apoptotic 
cells in TK6 cells rather than WTK-1 cells after 
5-FU treatment [25].  Inhibition of DNA synthesis by 
5-FU leads to nucleotide pool imbalance and induces 
DSBs.  When DNA was injured,  ATM phosphory-
lates TP53 protein,  and phosphorylated TP53 protein 
induces BAX,  FAS,  and so on,  which leads to the 
induction of apoptosis [35-37].  The increase of 
apoptosis in TK6 cells in previous studies might have 
been due to the up-regulation of genes involved in the 
TP53 pathway.
　 After 5-FU treatment,  G1 phase cells were accu-
mulated in TK6 cells,  whereas S phase cells were 
accumulated in WTK-1 cells [25].  Phosphorylated 
TP53 protein up-regulates the p21 gene,  which inhib-
its the eﬀect of CDK4 and leads to the G1 phase 
arrest [38,  39].  The diﬀerences in cell cycle arrest 
in TK6 and WTK-1 cells might be related to the dif-
ferences in gene expression between these cell lines.
　 No evidence that 5-FU is carcinogenic has been 
found in mice or rats.  In clinical trials,  there is no 
epidemiological study of 5-FU as a single agent.  
However,  5-ﬂuoro-2ʼ-deoxyuridine,  which has the 
same pharmacodynamic action as 5-FU,  was reported 
not to increase the risk of second malignancies.  
Therefore,  5-FU has been listed as not classiﬁable 
regarding its carcinogenicity to humans by the 
International Agency for Research on Cancer (IARC) 
[40].  This classiﬁcation appears to conform with our 
results that 5-FU induced no gene mutation and up-
regulated many genes involved in the TP53 pathway in 
TK6 cells (TP53 wild type).  However,  in WTK-1 cells 
(TP53 mutated cells),  gene mutation was induced by 
5-FU,  and a few genes related to the TP53 pathway 
were expressed.  The cells with mutated TP53 or 
defective DNA repair might show gene mutation (per-
haps leading to carcinogenicity and/or cancer progres-
sion) by 5-FU treatment.
　 The mutation frequency in Tk mutation assay is 
known to be induced by point mutation or chromo-
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somal aberration [41].  In this study,  it was unclear 
whether 5-FU induced point mutation or chromosomal 
aberration in mutated cells,  because the sequence in 
mutated genes was not analyzed.  However,  5-FU did 
not induce point mutation in Salmonella typhimurium 
[22] and increased the MN frequency,  which indicates 
the chromosomal aberration in WTK-1 cells but not in 
TK6 cells.  Therefore,  mutation frequency increased 
by 5-FU was caused due to the chromosomal aberra-
tion,  and the diﬀerence in degree of MN frequency 
between TK6 cells with WTK-1 cells might aﬀect 
mutation frequency.
　 In the present study,  5-FU induced gene mutation 
and chromosomal damage in TP53 mutated WTK-1 
cells but not TP53 wild-type TK6 cells after 24h 
treatment.  These diﬀerences in response to 5-FU 
were suggested as being due to the diﬀerence in gene 
expression related to the TP53 pathway,  especially 
the induction of apoptosis or cell cycle arrest after the 
DNA damage.  Since our results demonstrated that 
5-FU exerts less eﬀective cytotoxicity and stronger 
mutagenic eﬀects on TP53-mutated cells than on TP53-
wild type cells,  the clinical eﬃcacy of 5-FU will likely 
be higher in TP53-wild-type cancers than in TP53-
mutated cancers and the TP53 gene status may be 
responsible for the response to 5-FU therapy and the 
patient prognosis.  This important prediction has been 
recently conﬁrmed on patients with squamous cell 
carcinoma of the esophagus [42].
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